KEY TAKE AWAYS
- To define and intensively analyze the global oncology pharmaceuticals and therapeutics market.
- To identify and assess the market with respect to cancer drugs, vaccines and therapies currently available in the market and in the pipeline.
- To analyze comprehensively each of the market segmentation with respect to market drivers, restraints and opportunities that is impacting the market revenues and trend.
- To quantify and evaluate the market revenues for each of the micro markets with respect to drugs, vaccines and therapy revenues attributed to respective geographies (North America, Europe, Asia and Rest of the World).
- To analyze and comprehend the core competency of the market players by profiling the companies with respect to their product offering, revenues, target market, pricing, pipeline products, patents and recent developments. .
- To understand the competitive scenario by tracking an indicative strategy trend such as mergers & acquisitions, alliances, joint ventures etc. in the industry among the top market players.
MARKETS COVERED
2008 saw almost 12 million patients diagnosed with cancer. Despite, increasing technological advancements and research the deaths due to cancer were about 8 million people in 2008. Lung cancer accounts for the highest mortality rate. However, there has been a significant development in technologies and drugs/vaccines with respect to breast cancer, thyroid cancer, and pancreatic cancer therefore increasing the survival rates. However, the patients continue to live with a fear of cancer recurrence and hence pharmaceutical companies are currently focusing on providing anti-recurrence drugs and vaccines with minimal side effects. These drugs and vaccines are expected to dramatically increase the quality of life among the cancer survivors. With escalating awareness, Asian countries are increasingly demanding for novel therapies than ever before. The unmet demand in the market coerces the market players to clearly understand the competitive products/pipeline products, role of competitors, positioning and pricing aspects in order to boost their market position.
STAKEHOLDERS
This market report will enable strategic understanding on the oncology pharmaceuticals and therapeutics market
Each section of the report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints and opportunities. The report contains strategic section with respect to competitive landscape and market overview. The report will encompass more than 40 company profiles.
SUMMARY TABLE
|
Global Oncology Pharmaceuticals and Therapeutics market |
2007 |
2008 |
2009 |
2014 |
CAGR% 2009-2014 |
| Cancer drugs |
|
|
|
|
|
| Cancer vaccines |
|
|
|
|
|
| Cancer therapeutics market |
|
|
|
|
|
Key summary tables and description
MARKET OVERVIEW
- Extensive market segmentation of global oncology Pharmaceuticals and Therapeutics market.
- Market penetration model and top down approach for determining the market revenues for each of the markets by products and geography.
- Further assessment of the market withrespect to competitive landscape/ competitive products and pipeline products
Dummy tables
Summary table
|
Global Oncology Pharmaceuticals and Therapeutics market |
2007 |
2008 |
2009 |
2014 |
CAGR% (2009 – 2014) |
|
Geography |
|
|
|
|
|
|
US |
|
|
|
|
|
|
Europe |
|
|
|
|
|
|
Asia |
|
|
|
|
|
|
ROW |
|
|
|
|
|
SAMPLE TABLES
Cancer Drugs
|
Product |
2007 |
2008 |
2009 |
2014 |
CAGR% (2009 – 2014) |
|
Cytotoxics |
|
|
|
|
|
|
Antihormonals |
|
|
|
|
|
|
Molecular-targeted agents |
|
|
|
|
|
| Growth factors |
|
|
|
|
|
|
Total |
|
|
|
|
|
|
Global Cytotoxics Market |
2007 |
2008 |
2009 |
2014 |
CAGR% (2009 – 2014) |
|
Product |
|
|
|
|
|
|
Taxotere |
|
|
|
|
|
|
Paraplatin |
|
|
|
|
|
|
Eloxatin |
|
|
|
|
|
|
Gemzar |
|
|
|
|
|
|
Taxol |
|
|
|
|
|
|
Campto/camptosar |
|
|
|
|
|
|
Temodar/temodal |
|
|
|
|
|
|
Farmorubicin/ ellence |
|
|
|
|
|
|
Xeloda |
|
|
|
|
|
|
Uft |
|
|
|
|
|
|
Total |
|
|
|
|
|
|
Global Antihormonals Market |
2007 |
2008 |
2009 |
2014 |
CAGR% (2009 – 2014) |
|
Product |
|
|
|
|
|
|
Lupron |
|
|
|
|
|
|
Zoladex |
|
|
|
|
|
|
Arimidex |
|
|
|
|
|
|
Casodex |
|
|
|
|
|
|
Femara |
|
|
|
|
|
|
Total |
|
|
|
|
|
|
Global Molecular-targeted agents |
2007 |
2008 |
2009 |
2014 |
CAGR% (2009 – 2014) |
|
Product |
|
|
|
|
|
|
Iressa |
|
|
|
|
|
|
Avastin |
|
|
|
|
|
|
Erbitux |
|
|
|
|
|
|
Glivec |
|
|
|
|
|
|
MabThera/Rituxan |
|
|
|
|
|
|
Herceptin |
|
|
|
|
|
|
Total |
|
|
|
|
|
| Anti Recurrence – Breast Cancer Drugs & Therapies |
2007 |
2008 |
2009 |
2014 |
CAGR% (2009 – 2014) |
|
Product |
|
|
|
|
|
|
Adjuvant therapy |
|
|
|
|
|
|
Hormone Therapy Drugs/Vaccines |
|
|
|
|
|
|
Radiation therapy |
|
|
|
|
|
|
Others |
|
|
|
|
|
|
Total |
|
|
|
|
|
|
Anti Recurrence – Breast Cancer Drugs & Therapies – Hormone Therapy Drugs/Vaccines Market |
2007 |
2008 |
2009 |
2014 |
CAGR% (2009 – 2014) |
|
Product |
|
|
|
|
|
|
Selective estrogen receptor modulators (SERMs). |
|
|
|
|
|
|
Aromatase inhibitor (AI) |
|
|
|
|
|
|
Combination Drugs Therapy |
|
|
|
|
|
|
Total |
|
|
|
|
|
TABLE OF CONTENT
1. Introduction
1.1. KEY TAKE AWAYS
1.2. Report description
1.3. Markets Covered
1.4. STAKEHOLDERS
2. Summary
3. Market Overview
4. Ophthalmic devices market
4.1. MARKET OVERVIEW
4.1.1. Market introduction
4.1.1.1. Market definition
4.1.1.2. Types of cancer
4.2. Statistics
4.3. Probability of success for different kinds of treatments
4.4. Others
4.5. HIGH LEVEL MARKET ANALYSIS
4.5.1. Pricing trends
4.5.2. Positioning
4.5.3. Clinical trials
4.5.4. Comparative analysis - types of treatments (drugs/vaccines/therapies/others) (oral/intravenous)
4.5.5. Unmet needs & technology developments
4.5.6. Competitive landscape – entry barriers
4.5.7. Geographic analysis
4.5.8. Patent analysis
4.6. CANCER DRUGS
4.6.1. Cytotoxics
4.6.1.1. Taxotere (docetaxel)
4.6.1.2. Paraplatin (carboplatin)
4.6.1.3. Eloxatin (oxaliplatin)
4.6.1.4. Gemzar (gemcitabine)
4.6.1.5. Taxol (paclitaxel)
4.6.1.6. Campto/camptosar (irinotecan)
4.6.1.7. Temodar/temodal (temozolomide)
4.6.1.8. Farmorubicin/ ellence (epirubicin)
4.6.1.9. Xeloda (capecitabine)
4.6.1.10. Uft (tegafur-uracil)
4.6.2. Antihormonals
4.6.2.1. Lupron (leuprorelin)
4.6.2.2. Zoladex (goserelin)
4.6.2.3. Arimidex (anastrozole)
4.6.2.4. Casodex (bicalutamide)
4.6.2.5. Femara (letrozole)
4.6.3. Molecular-targeted agents
4.6.3.1. Iressa (gefitinib)
4.6.3.2. Avastin (bevacizumab)
4.6.3.3. Erbitux (cetuximab)
4.6.3.4. Glivec (imatinib) monoclonal antibodies
4.6.3.5. Mabthera/rituxan (rituximab)
4.6.3.6. Herceptin (trastuzumab)
4.6.4. Anti-emetics
4.6.4.1. Kytril (granisetron) and zofran (ondansetron)
4.6.4.2. Others
4.6.5. Growth factors
4.6.5.1. Neupogen (filgrastim)
4.6.5.2. Neulasta (pegylated filgrastim)
4.6.5.3. Epogen (epoetin alfa)
4.6.5.4. Erypo/ procrit (epoetin alfa)
4.6.5.5. Recormon/epogin (epoetin beta)
4.6.5.6. Aranesp (darbopoetin)
4.7. CANCER VACCINES
4.7.1. THERAPEUTIC CANCER VACCINES
4.7.1.1. Whole-cell vaccines
4.7.1.2. Gene modified cancer vaccines
4.7.1.3. Dendritic cell cancer vaccines
4.7.1.4. Peptide cancer vaccines
4.7.1.5. Bacterial vector vaccines
4.7.1.6. Heat-shock protein vaccines
4.7.1.7. Viral vector vaccines
4.7.1.8. DNA vaccines
4.7.2. PROPHYLACTIC VACCINES
4.7.2.1. Hepatitis B vaccine
4.7.2.2. Others (Eg:Gardasil)
4.8. THERAPEUTICS MARKET
4.8.1. CHEMOTHERAPY
4.8.1.1. Alkylating Agents
4.8.1.2. Antimetabolites
4.8.1.3. Cytotoxic Agents
4.8.1.4. Plant Derivatives
4.8.2. GENE THERAPIES
4.8.2.1. Gene therapy cancer vaccines
4.8.2.2. Antisense technology
4.8.2.3. Initiation of cell-mediated immunity
4.8.2.4. Tumor suppresser genes
4.8.3. OTHERS
4.8.3.1. Hormone Therapy Drugs/Vaccines
4.8.3.2. Others (As discussed below specifically for breast & lung cancer will also be included at a general level)
5. Anti Recurrence – Breast Cancer Drugs & Therapies
5.1. Adjuvant therapy
5.1.1. Adjuvant chemotherapy
5.1.1.1. Orally (by mouth)
5.1.1.2. Injection (blood vessel)
5.2. Hormone Therapy Drugs/Vaccines
5.2.1. Selective estrogen receptor modulators (SERMs).
5.2.1.1. Tamoxifen is an antiestrogen (estrogen suppressor) medication – Molecule
5.2.1.2. Tamoxifen citrate
5.2.1.3. Fulvestrant
5.2.1.4. Nolvadex,
5.2.1.5. Soltamox,
5.2.1.6. Tamofen
5.2.1.7. Others
5.2.2. Aromatase inhibitor (AI)
5.2.2.1. Femara
5.2.2.2. Others
5.2.3. Combination Drugs Therapy
5.3. RADIATION THERAPY
5.3.1. External beam radiotherapy
5.3.2. Stereotactic Radiotherapy
5.3.2.1. Virtual simulation, 3-dimensional conformal radiotherapy, and intensity-modulated radiotherapy
5.3.2.2. Particle Therapy
5.3.2.3. Radioisotope Therapy (RIT)
5.3.2.4. Brachytherapy
5.3.3. Surgical methods (ovarian ablation)
5.3.4. Chemotherapy
5.3.4.1. Orally
5.3.4.2. Intravenously
5.4. OTHERS
6. Lung Cancer Drugs & Therapies
6.1. FAST TRACK DRUGS
6.1.1. Vaccine
6.1.2. Oral medication
6.1.3. Chemotherapy drug
6.1.4. Treatment drug
6.2. CYTOTOXICS
6.3. TUMOR ABLATION
6.3.1. Radiofrequency ablation (RFA),
6.3.2. Cryogenic
6.3.3. Chemicals
6.3.4. Others
7. Competitive Drugs/Vaccines for Cancers
7.1. Faslodex
7.2. Imc-c225
7.3. Gemzar
7.4. Theratope
7.5. Evista
7.6. Cetrotide
7.7. Provenge
7.8. Abarelix
7.9. Iressa
7.10. Mitumomab
7.11. Rhumab-vegf
7.12. Isis 3521
7.13. Alimta
7.14. Eniluracil (776c85)
7.15. Su5416
7.16. Thalomid (thalidomide)
7.17. Iressa
7.18. Gastrimmune
7.19. Rubitecan
7.20. Glivec (sti 571)
7.21. Campath (alemtuzumab)
7.22. Nelarabine (gw506u78)
7.23. Rituxan (rituximab)
7.24. Zd0473
7.25. Rubitecan
7.26. Taxotere
7.27. Gliadel wafer
7.28. Xcytrin
7.29. Cotara
7.30. Irofulven
7.31. Avicine
7.32. Rubitecan
7.33. Photofrin
7.34. Targretin
7.35. Imc-c225
7.36. Foscan
8. Companies (Company Overview, Product Portfolio, Target Market, USP, Revenues, Pipeline Products, Recent Developments, Patents)
8.1. Amgen
8.2. Novartis
8.3. Roche
8.4. Sanofi-aventis
8.5. Genentech
8.6. Astrazeneca
8.7. Johnson & johnson
8.8. Jiangsu hansen pharmaceutical co., ltd.(hansen pharma)
8.9. Bristol-myers squibb
8.10. Pfizer
8.11. Glaxosmithkline
8.12. Eli lilly
9. THERAPEUTIC CANCER VACCINES
9.1. Avax technologies
9.2. M-vax
9.3. Intracel
9.4. Corixa
9.5. Melacine
9.6. Provenge
10. PIPELINE PRODUCTS
10.1. Retinoids
10.2. Selenium
10.3. Cdx-110
10.4. Nilutamide
10.5. Geron
10.6. Panvac-vf
10.7. alloverctin7
10.8. stimuvax
10.9. Affinitac
10.10. Advaxis and live listeria vaccines
10.11. Trangene
10.12. Others
MarketsandMarkets.com publishes about 120 report a year across 10 main industries. The reports are exhaustive reports with about 50 micro markets and product segments, about 80 to 100 market data summary tables, 50 short company profiles, market breakdown upto 5 levels, strategic and competitive landscape, patent overview of more than 300 patents.
MarketsandMarkets.com publishes about 120 report a year across 10 main industries. The reports are exhaustive reports with about 50 micro markets and product segments, about 80 to 100 market data summary tables, 50 short company profiles, market breakdown upto 5 levels, strategic and competitive landscape, patent overview of more than 300 patents.